SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CA variants in breast cancers

European Journal of Human Genetics

Volumn 25, Issue 3, 2017, Pages 384-387

  Puzone, Roberto ^a   Pfeffer, Ulrich ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CA; SETD9 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; MAP3K1 PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN;

ARTICLE; CANCER PATIENT; CANCER RISK; CHROMOSOME 5Q11.2 DELETION; CHROMOSOME DELETION; COHORT ANALYSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; ODDS RATIO; PENETRANCE; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; VALIDATION PROCESS; BREAST TUMOR; CHROMOSOME 5; GENETICS; MUTATION; PLEIOTROPY;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; GENETIC PLEIOTROPY; HUMANS; MAP KINASE KINASE KINASE 1; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 85007485838     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2016.179     Document Type: Article

References (22)

1. Foulkes WD: Inherited susceptibility to common cancers. N Engl J Med 2008; 359: 2143-2153
2. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA: Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31: 33-36
3. Mucci LA, Hjelmborg JB, Harris JR et al: Familial risk and heritability of cancer among twins in Nordic countries. JAMA 2016; 315: 68-76
4. Michailidou K, Beesley J, Lindstrom S et al: Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 2015; 47: 373-380
5. Harlid S, Ivarsson MI, Butt S et al: Combined effect of low-penetrant SNVs on breast cancer risk. Br J Cancer 2012; 106: 389-396
6. Stephens PJ, Tarpey PS, Davies H et al: The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 400-404
7. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70
8. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature 2009; 458: 719-724
9. O'Brien KM, Cole SR, Engel LS et al: Breast cancer subtypes and previously established genetic risk factors: a bayesian approach. Cancer Epidemiol Biomarkers Prev 2014; 23: 84-97
10. Li Q, Seo JH, Stranger B et al: Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 2013; 152: 633-641
11. Lu PH, Yang J, Li C et al: Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59 977 subjects. Breast Cancer Res Treat 2011; 126: 663-670
12. Rhie SK, Coetzee SG, Noushmehr H et al: Comprehensive functional annotation of seventy-one breast cancer risk Loci. PLoS One 2013; 8: e63925
13. Ellis MJ, Ding L, Shen D et al: Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-360
14. Tryka KA, Hao L, Sturcke A et al: NCBI's Database of Genotypes and Phenotypes: dbGaP. Nucleic Acids Res 2014; 42: D975-D979
15. Wilks C, Cline MS, Weiler E et al: The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data. Database 2014; e-pub ahead of print 29 September 2014; doi:10.1093/database/bau093
16. Cerami Gao J, Dogrusoz U et al: The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401
17. Nyholt DR: A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-769
18. Glubb DM, Maranian MJ, Michailidou K et al: Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. Am J Hum Genet 2015; 96: 5-20
19. Aksamitiene E, Kiyatkin A, Kholodenko BN: Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans 2012; 40: 139-146
20. Britten CD: PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol 2013; 71: 1395-1409
21. Lu Z, Xu S, Joazeiro C, Cobb MH, Hunter T: The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol Cell 2002; 9: 945-956
22. Xia Y, Wang J, Xu S, Johnson GL, Hunter T, Lu Z: MEKK1 mediates the ubiquitination and degradation of c-Jun in response to osmotic stress. Mol Cell Biol 2007; 27: 510-517